Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
Tiantai, ZJ, CN
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.97% | -7.34% | -12.26% | -25.28% | -12.45% | -20.84% | -5.80% | -25.17% | +33.99% | +64.56% | +64.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+15.0% ★ Q1'26: -3.2% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+23.6% ★ Q1'26: -46.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+14.3% Q1'26: -5.6% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+32.6% ★ Q1'26: +22.2% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+17.5% ★ Q1'26: +10.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.4% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.52× ★ Q1'26: 2.81× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
803.36M
est: 819.00M (-1.9%)
|
1.01B
est: 1.07B (-5.6%)
|
1.26B
est: 1.44B (-12.4%)
|
1.48B
est: 1.51B (-1.9%)
|
1.70B
est: 1.70B (-0.2%)
|
1.90B
1.90B – 1.90B
+11.5% YoY
|
2.14B
2.14B – 2.14B
+12.9% YoY
|
2.41B
2.41B – 2.41B
+12.6% YoY
|
| EBITDA |
244.65M
est: 240.69M (+1.6%)
|
307.35M
est: 313.87M (-2.1%)
|
406.88M
est: 715.35M (-43.1%)
|
505.55M
est: 747.36M (-32.4%)
|
678.98M
est: 844.69M (-19.6%)
|
941.78M
941.78M – 941.78M
+11.5% YoY
|
1.06B
1.06B – 1.06B
+12.9% YoY
|
1.20B
1.20B – 1.20B
+12.6% YoY
|
| EBIT |
193.18M
est: 193.72M (-0.3%)
|
242.41M
est: 252.62M (-4.0%)
|
332.73M
est: 605.49M (-45.0%)
|
424.19M
est: 632.58M (-32.9%)
|
553.01M
est: 714.97M (-22.7%)
|
797.14M
797.14M – 797.14M
+11.5% YoY
|
899.91M
899.91M – 899.91M
+12.9% YoY
|
1.01B
1.01B – 1.01B
+12.6% YoY
|
| Net Income |
168.71M
est: 171.42M (-1.6%)
|
210.96M
est: 227.23M (-7.2%)
|
289.42M
est: 377.98M (-23.4%)
|
354.79M
est: 390.68M (-9.2%)
|
449.21M
est: 465.54M (-3.5%)
|
490.05M
490.05M – 490.05M
+5.3% YoY
|
577.85M
577.85M – 577.85M
+17.9% YoY
|
669.73M
669.73M – 669.73M
+15.9% YoY
|
| SGA |
136.00M
est: 146.08M (-6.9%)
|
175.27M
est: 190.50M (-8.0%)
|
270.49M
est: 244.78M (+10.5%)
|
300.70M
est: 255.73M (+17.6%)
|
150.13M
est: 289.03M (-48.1%)
|
322.25M
322.25M – 322.25M
+11.5% YoY
|
363.80M
363.80M – 363.80M
+12.9% YoY
|
409.51M
409.51M – 409.51M
+12.6% YoY
|
| EPS |
0.42
est: 0.43 (-2.3%)
|
0.52
est: 0.57 (-8.8%)
|
0.71
est: 0.93 (-23.3%)
|
0.89
est: 0.96 (-7.0%)
|
1.12
est: 1.14 (-1.8%)
|
1.20
1.20 – 1.20
+5.3% YoY
|
1.42
1.42 – 1.42
+17.9% YoY
|
1.64
1.64 – 1.64
+15.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 2/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 121.7K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 52.4K | 0.28% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 34.0K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dingjun Chu | GM & Director | — | male |
| Fangfang Li | Board Secretary | — | female |
| Guoping Wang | Deputy GM & Director | — | male |
| Jieming Chen | Deputy General Manager | — | male |
| Liqin Zhang | Deputy GM & Director of Sales | — | female |
| Mingyan Xin | Deputy General Manager | — | female |
| Xiuyu Wang | Deputy GM, Accounting Supervisor & Financial Director | — | female |
| Zhenping Zhao | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 605116.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
